Health X Platform Ltd reported FY26 revenue of ₹1,283 crore with a marginal PAT loss of ₹1.4 crore. The company is demerging its finance division and has set a long-term revenue target of ₹6,000 crore by FY30.

Health X Platform Ltd FY26 Results and Demerger

FY26 Revenue: ₹1,283 crore
FY26 PAT Loss: ₹1.4 crore

Reader Takeaway: Revenue growth is positive, but continued losses and a pending demerger are key points.

What just happened

Health X Platform Limited, formerly Sastasundar Ventures, reported its financial results for FY26. The company achieved a revenue of ₹1,283 crore, with a net loss after tax (PAT) of ₹1.4 crore. The EBITDA loss for the fiscal year stood at ₹65 crore. In the fourth quarter (Q4 FY26), revenue was ₹356 crore, and the PAT loss was ₹12.9 crore.

Why this matters

Despite a significant revenue figure, the company continues to incur losses, albeit reduced at the PAT level for the full year. The planned demerger of its Finance Division into Microsec Resources Ltd aims to streamline operations and unlock value by separating the healthcare business from financial assets. This move could simplify the corporate structure for investors.

The backstory

Health X Platform is transitioning into a broader healthcare ecosystem, focusing on its B2C Sastasundar App and B2B Retailer Shakti platform. A new genetic medicine category, JITO, was launched, contributing ₹0.3 crore in its first quarter.

What changes now

The Board has approved a scheme of arrangement to demerge the finance division. Shareholders will receive one share of Microsec Resources Ltd for every three shares held in Health X Platform Ltd. Post-demerger, Health X is expected to retain ₹400 crore of the treasury for growth, with ₹100 crore going to Microsec Resources.

Risks to watch

The company faces concerns regarding continued profitability, with ongoing EBITDA losses. Management is also exercising caution with AI product rollouts due to market unreadiness and is cautious about credit exposure in its hospital business, opting for cash-and-carry operations.

Peer comparison

While specific peers are not mentioned in the filing, companies operating in the broader healthcare and e-commerce pharmaceutical space in India would be relevant comparators for revenue growth and profitability metrics.

Context metrics (time-bound)

Health X Platform reported a working capital cycle of 18 days and a total capital employed of ₹74 crore, with a cash balance of ₹30 crore as of FY26.

What to track next

Investors will be watching the execution of the planned ₹234 crore capital expenditure, funded by bank loans and treasury funds. Progress in the JITO category and the overall revenue growth towards the long-term target of ₹6,000 crore by FY30 will be crucial indicators.